Literature DB >> 2741194

Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models.

R D Pryka1, K A Rodvold, M Garrison, J C Rotschafer.   

Abstract

The absolute and relative predictive performances of one- and two-compartment Bayesian forecasting models were evaluated and compared. Initial population parameters were derived from 25 adult patients with stable renal function and who were being treated for presumed or documented gram-positive infections. The performance of each model was compared using these population parameters with and without steady-state or non-steady-state feedback concentrations to predict future peak and trough concentrations in an additional 20 patients. Both models tended to underpredict vancomycin peak and trough concentrations obtained at steady state. The use of a two-compartment model resulted in statistically less bias and more precise predictions of vancomycin peak concentrations when either population parameters or non-steady-state concentrations were used for future predictions. No difference in model performance was observed when steady-state concentrations were used to predict future steady-state concentrations. The results of this evaluation demonstrate that the two-compartment Bayesian model is less biased and more precise in determining future vancomycin serum concentrations given only population parameters or non-steady-state feedback information. No difference in model performance could be discerned when steady-state concentrations were used as feedback information.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2741194

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  16 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Bayesian forecasting of serum gentamicin concentrations in intensive care patients.

Authors:  K A Rodvold; R D Pryka; P G Kuehl; R A Blum; P Donahue
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

5.  Vancomycin Pharmacokinetics in Patients with Advanced Cancer Near End of Life.

Authors:  Hirokazu Nakayama; Masahiro Suzuki; Toshiaki Kato; Hirotoshi Echizen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

6.  Are higher vancomycin doses needed in ventricle-external shunted patients?

Authors:  Meritxell Pujal; Dolors Soy; Carles Codina; Josep Ribas
Journal:  Pharm World Sci       Date:  2006-10-26

7.  Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.

Authors:  Anthony M Casapao; Thomas P Lodise; Susan L Davis; Kimberly C Claeys; Ravina Kullar; Donald P Levine; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

8.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.

Authors:  A K Hurst; M A Yoshinaga; G H Mitani; K A Foo; R W Jelliffe; E C Harrison
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 9.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

10.  Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Nicholas S Britt; Nimish Patel; Rebecca T Horvat; Molly E Steed
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.